Back Pain News and Research

Latest Back Pain News and Research

FDA approves Forest Labs' Daliresp to treat COPD

Forest Laboratories, Inc. announced today that Daliresp was approved by the U.S. Food and Drug Administration as a treatment to reduce the risk of chronic obstructive pulmonary disease exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.

1 Mar 2011

Researchers combine old bones and new technology to treat chronic back pain

The bones of people who died up to a hundred years ago are being used in the development of new treatments for chronic back pain. It is the first time old bones have been used in this way.

1 Mar 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion Pharmaceuticals, Inc. joins the European Organization for Rare Diseases, the National Organization for Rare Disorders and families, governments, companies and medical communities around the world in observing the fourth annual Rare Disease Day today.

28 Feb 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Amgen today announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA to Zometa in preventing bone complications called skeletal-related events in 1,901 men with prostate cancer and bone metastases.

25 Feb 2011

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Genentech, a member of the Roche Group, today announced the U.S. Food and Drug Administration (FDA) has granted a hearing to allow the company the opportunity to present its views on why Avastin® (bevacizumab) should remain FDA-approved for metastatic breast cancer (mBC). The FDA has scheduled the hearing for June 28 to 29, 2011.

25 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Medtronic: Kyphon Balloon Kyphoplasty provides better back pain relief in cancer patients

Medtronic Inc., today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients. The study found that Kyphon Balloon Kyphoplasty provided cancer patients better back-specific function, more rapid back pain relief and improved quality of life compared with non-surgical care one month after treatment.

17 Feb 2011

Study finds worse outcomes in workers undergoing spinal fusion surgery

For workers' compensation patients with chronic low back pain, spinal fusion surgery leads to worse long-term outcomes—including a lower rate of return to work—compared to nonsurgical treatment, suggests a study in the February 15th issue of Spine. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

16 Feb 2011

Patients with chronic low-back pain can benefit from spinal manipulation

If you're suffering from chronic lower back pain, a new review of existing research finds that spinal manipulation − the kind of hands-on regimen that a chiropractor might perform on you − is as helpful as other common treatments like painkillers.

15 Feb 2011

Research: 75% of nonmilitary group medically evacuated for nonbattle injuries did not return to field

After analyzing data on 2,155 private contractors, diplomats and other civilians supporting war efforts in Iraq and Afghanistan who were medically evacuated out of combat zones, researchers have found they are more likely to be evacuated for noncombat-related injuries, but more likely to return to work in-country after treatment for these conditions.

15 Feb 2011

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix, Inc. announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

10 Feb 2011

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

The New England Journal of Medicine (NEJM) published a study today that shows Afinitor® (everolimus) tablets plus best supportive care (BSC) more than doubled progression-free survival (PFS), or time without tumor growth, versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (NET).

10 Feb 2011

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that OCEANS, a Phase III study evaluating Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until disease progression in women with previously treated (recurrent), platinum-sensitive ovarian cancer, met its primary endpoint.

8 Feb 2011

Back Pain News and Research

Latest Back Pain News and Research

FDA approves Forest Labs' Daliresp to treat COPD

Researchers combine old bones and new technology to treat chronic back pain

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

The Lancet journal publishes XGEVA Phase 3 study results against prostate cancer, bone metastases

Genentech granted FDA hearing on Avastin for metastatic breast cancer

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Medtronic: Kyphon Balloon Kyphoplasty provides better back pain relief in cancer patients

Study finds worse outcomes in workers undergoing spinal fusion surgery

Patients with chronic low-back pain can benefit from spinal manipulation

Research: 75% of nonmilitary group medically evacuated for nonbattle injuries did not return to field

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Afinitor plus BSC doubles progression-free survival in patients with advanced pancreatic neuroendocrine tumors

Genentech's OCEANS Phase III study of Avastin in platinum-sensitive ovarian cancer meets primary endpoint

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

AHRQ finds 3.4 million emergency department visits for back problems in the U.S.

New study indicates predisposition to lumbar disc disease could be inherited

ACP finds diagnostic imaging for low back pain does not improve patients health

Abbott fourth quarter worldwide sales increase 13.4% to nearly $10 billion

UWE researcher receives two CSPCT grants to improve clinical delivery of treatments

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in